Emery–Dreifuss muscular dystrophy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Emery–Dreifuss muscular dystrophy | |
|---|---|
| Synonyms | EDMD |
| Pronounce | |
| Specialty | Neurology, Genetics |
| Symptoms | Muscle weakness, joint contractures, cardiac arrhythmias |
| Complications | N/A |
| Onset | Childhood to early adulthood |
| Duration | Lifelong |
| Types | X-linked, autosomal dominant, autosomal recessive |
| Causes | Genetic mutations in EMD, LMNA, FHL1 genes |
| Risks | Family history of the condition |
| Diagnosis | Genetic testing, Electromyography, Muscle biopsy |
| Differential diagnosis | Duchenne muscular dystrophy, Becker muscular dystrophy, Limb-girdle muscular dystrophy |
| Prevention | N/A |
| Treatment | Physical therapy, Cardiac monitoring, Pacemaker |
| Medication | |
| Prognosis | Variable, depends on cardiac involvement |
| Frequency | Rare |
| Deaths | N/A |


Emery–Dreifuss muscular dystrophy is a condition that primarily affects muscles used for movement, such as skeletal muscles, and also affects the cardiac muscle. It is named after Alan Eglin H. Emery and Fritz E. Dreifuss.
Signs and symptoms[edit]
Symptoms of Emery–Dreifuss muscular dystrophy (EDMD) typically begin in teenage years and may include:
Other signs include:
- Muscle weakness in the shoulders and lower legs
- Cardiac issues such as bradycardia and palpitations
- Slow-developing muscle contractures, eventually requiring orthopedics
Genetics[edit]
Emery–Dreifuss muscular dystrophy can be caused by mutations in several genes, including:
- EMD: Produces the emerin protein, critical for skeletal and cardiac muscle function.
- LMNA: Produces lamin A and C proteins, vital for nuclear envelope integrity.
- SYNE1, SYNE2, FHL1, and TMEM43: Associated with specific subtypes of EDMD.
| Type | OMIM | Gene | Description |
|---|---|---|---|
| EDMD1 | Online Mendelian Inheritance in Man (OMIM) 310300 | EMD | Mutations lead to a lack of functional emerin, affecting skeletal and cardiac muscles. |
| EDMD2, EDMD3 | Online Mendelian Inheritance in Man (OMIM) 181350 | LMNA | Mutations alter lamin A and lamin C proteins, leading to impaired nuclear envelope function. |
| EDMD4 | Online Mendelian Inheritance in Man (OMIM) 612998 | SYNE1 | Associated with cerebellar ataxia and nuclear envelope abnormalities. |
| EDMD5 | Online Mendelian Inheritance in Man (OMIM) 612999 | SYNE2 | Mutations disrupt gene function, leading to nuclear envelope defects. |
| EDMD6 | Online Mendelian Inheritance in Man (OMIM) 300696 | FHL1 | Associated with x-linked EDMD, showing decreased protein expression. |
| EDMD7 | Online Mendelian Inheritance in Man (OMIM) 614302 | TMEM43 | Mutations affect nuclear envelope consistency. |
Diagnosis[edit]
Diagnosis of Emery–Dreifuss muscular dystrophy involves:
- CAT scan
- Serum CK analysis
- EKG
- Echocardiogram
- Electromyogram
- Immunodetection
Classification[edit]
EDMD types are categorized by inheritance patterns:
- X-linked: Caused by mutations in the EMD gene.
- Autosomal dominant: Characterized by skeletal muscle weakness and cardiac issues.
- Autosomal recessive: Includes cardiac complications, such as arrhythmias.
Treatment[edit]
Management of EDMD focuses on addressing complications and may include:
- Orthopedics and surgery
- Monitoring and treating cardiac issues with medications like beta-blockers and ACE inhibitors
- Respiratory support
- Physical therapy
See also[edit]
| Muscular dystrophy | ||||||||
|---|---|---|---|---|---|---|---|---|
* Category
|
| Diseases of muscle, neuromuscular junction, and neuromuscular disease | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| X-linked disorders |
|---|
|
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian